

**** Important Information ****

The following is information regarding the upcoming TennCare 2016-2017 Synagis® Season:

TennCare's clinical criteria for the coverage of Synagis® reflects current published American Academy of Pediatrics (AAP) guidelines for the treatment of Respiratory Syncytial Virus (RSV). Please read further for a summary of the clinical criteria for the 2016-2017 RSV treatment season.

Synagis® will be approved for the following based on the infant/child age at the start of RSV season (11/1):

- < 12 months (1st year of life)
 - Gestational Age (GA) <29 weeks, 0 days (otherwise healthy)
 - Chronic Lung Disease of prematurity (GA <32 weeks, 0 days and > 21% O₂ x first 28 days after birth)
 - Anatomic pulmonary abnormalities, or neuromuscular disorder, or congenital anomaly that impairs the ability to clear secretions
 - Profoundly immunocompromised
 - Cystic Fibrosis with Chronic Lung Disease and/or nutritional compromise
- ≤ 12 months (1st year of life)
 - Congenital Heart Disease (hemodynamically *significant*) with *acyanotic* Heart Disease on Congestive Heart Failure medications and are potential candidates for cardiac surgery or moderate to severe Pulmonary Hypertension.
 - For *cyanotic* heart defects, PA must be on recommendation of a pediatric cardiologist
- > 12 months (2nd year of life)
 - Chronic Lung Disease of prematurity (GA <32 weeks, 0 days and > 21% O₂ x first 28 days after birth) and medical support (chronic systemic steroids, diuretic therapy, or supplemental O₂) within 6 months before start of 2nd RSV season
 - Cystic Fibrosis with documentation of severe lung disease or weight for length <10th percentile
- < 24 months (2nd year of life)
 - Cardiac transplant during RSV season
 - Already on prophylaxis and eligible: give post-op dose after cardiac bypass or after ECMO
 - Profoundly immunocompromised

Please also note the information below for the claims billing process:

- Magellan will begin accepting Synagis® Prior Authorization requests on 10/1/2016

- **Claims will be paid ONLY between 11/1/2016 and 4/30/2017 for all members** including members who have other primary coverage.
 - Claims billed prior to 11/1/2016 and after 4/30/2017 will not be eligible for primary or secondary billing to TennCare and will not be reimbursed.
 - **Please ensure that claims for Synagis® for TennCare enrollees are not processed prior to 11/1/2016, and Synagis® is NOT dispensed prior to 11/1/2016.**
- Despite differences in beginning and ending dates to RSV season in some states or regions, only a maximum of 5 doses will be approved during RSV season. If prophylaxis is initiated later in the RSV season, the infant or child will receive less than 5 doses.
 - For example, if prophylaxis is initiated in January, the 4th and final dose will be administered in April.
 - For eligible infants born during RSV season, fewer than 5 monthly doses may be needed.
- **Requirements for dispensing RSV Preventative agents are listed in section 2.26 of the Participating Pharmacy Agreement for Specialty Pharmacy providers found at <https://tenncare.magellanhealth.com>**
 - The initial prescription of any newly prescribed RSV Preventative Agents shall be shipped to the office of the Prescriber who will be administering the medication to the Covered TennCare Member.
 - The Pharmacy **shall** include the RSV Preventative Agents MAR (found with TennCare Synagis PA form at https://tenncare.magellanhealth.com/static/docs/Prior_Authorization_Forms/TennCare_Synagis_PA_Request_Form.pdf) with the initial prescription and each subsequent refill of said prescription.
 - The Pharmacy **shall** ensure that the RSV Preventative Agents MAR is completed by an agent of the prescriber who administered the RSV Preventative Agent and that said MAR is returned to the Pharmacy which dispensed the medication.
 - The Pharmacy **shall** maintain an electronic and/or a hard copy of the signed RSV Preventative Agents MAR for each dose of RSV Preventative Agent administered **prior to the dispensing of any additional refills** of said medication.
 - All signed MARs for dispensed RSV Preventative Agent **shall** be retained by the Pharmacy for no less than two (2) years from the date of each fill and be readily retrievable for inspection and audit per Tennessee law.
 - The absence of such RSV Preventative Agents MAR may be considered a material breach of contract by the dispensing Pharmacy. Such findings may result in monetary claim recoupment and subject the Specialty Pharmacy to immediate termination from the TennCare Pharmacy Network.
 - **AUTOMATIC REFILLS OF RSV PREVENTATIVE AGENTS ARE PROHIBITED BY THE TENNCARE PROGRAM.**

For further questions, please contact the Magellan Provider Educators at:

TNProviderEducation@magellanhealth.com